Evaluation of Efficay & Safety of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-2 Study

• Status: Completed
• Trial end date: 2018-10-05

Summary

The main purpose of this study is to evaluate the efficacy and safety of the study drug known as galcanezumab in participants with episodic migraine.

• Phase: Phase 3

Details

• Lead Sponsor: Eli Lilly and Company